SCHEMBL7210472

SCHEMBL7210472

Fc1ccc(-c2cnc(Cl)nc2-c2ccncc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.50
MAPK13 O15264 11/20 0.50
MAPK12 P53778 11/20 0.50
MAPK11 Q15759 11/20 0.50
ADORA1 P30542 2/20 0.50
CSNK1D P48730 2/20 0.50
CSNK1E P49674 1/20 0.50
MAPK10 P53779 2/20 0.49
ADORA2A P29274 1/20 0.48
GCGR P47871 2/20 0.46
MAPK9 P45984 2/20 0.45
RAF1 P04049 1/20 0.45
SRC P12931 1/20 0.45
BRAF P15056 1/20 0.45
KDR P35968 1/20 0.45
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
FRK P42685 1/20 0.44
CSNK1A1 P48729 1/20 0.44
GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6102065 0.87 ADORA2A (0.50) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL6102720 0.87 ADORA2A (0.50) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL7210423 0.83 ADORA1 (0.51) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL7215179 0.81 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL7210550 0.81 ADORA1 (0.75) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL7222483 0.81 ADORA1 (0.75) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL7215030 0.79 BRAF (0.51) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL7211811 0.78 PTGS2 (0.68) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL7211815 0.78 MEN1 (0.54) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL7210528 0.78 ADORA1 (0.61) MAPK14MAPK13MAPK12MAPK11ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610698-B2 Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases AMGEN, INC. 2003-08-26 US disclosed
EP-1314731-A2 Substituted pyrimidine compounds and their use AMGEN INC. (US) 2003-05-28 EP disclosed
EP-1314732-A2 Substituted pyrimidine compounds and their use AMGEN INC. (US) 2003-05-28 EP disclosed
US-20030069425-A1 Substituted pyrimidine compounds and methods of use AMGEN INC. 2003-04-10 US disclosed
US-6410729-B1 ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS AMGEN INC. 2002-06-25 US disclosed
CN-1246858-A Substituted pyrimidine compounds and their use AMGEN INC (US) 2000-03-08 CN disclosed
EP-0948497-A2 SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE Amgen inc. (US) 1999-10-13 EP disclosed
WO-1998024782-A2 SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069425-A1 Substituted pyrimidine compounds and methods of use DPYD, IL6, IL1B MAPK14 2062/4885MAPK13 2250/4885MAPK12 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.